Therapeutic Effect of New Biologics in Crohn's Disease

Last updated: December 3, 2023
Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Ulcerative Colitis

Colic

Inflammatory Bowel Disease

Treatment

N/A

Clinical Study ID

NCT04923100
2021ZSLYEC-066
  • Ages 17-80
  • All Genders

Study Summary

New types of biologics have brought advantages in therapy strategies for Crohn's disease. However, clinical data evaluating their efficacy and adverse in China is lacking. We aimed to evaluate the short-term and long-term therapeutic effect as well as drug adverse of Ustekinumab (UST) and Vedolizumab (VED). Besides, we aim to figure out the independent factors predicting the effectiveness of new biologics. Relations between drug exposure (trough concentration and antibody concentration) and therapeutic efficacy are study in-depth by this retrospective observational study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Consecutive adult patients with confirmed diagnosis of Crohn's disease andadministration of new type biologics.

Exclusion

Exclusion Criteria:

  • loss of follow-up, incomplete clinical data, without confirmed diagnosis

Study Design

Total Participants: 50
Study Start date:
June 10, 2021
Estimated Completion Date:
March 29, 2025

Connect with a study center

  • the Sixth Affiliated Hospital of Sun Yat-Sen University

    Guangzhou, Guangdong 501655
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.